| Autor: |
Vollaard A; RIVM, Centrum Infectieziektebestrijding, Bilthoven., Gieling EM; UMC Utrecht, afd. Klinische Farmacie, Utrecht.; Contact: E.M. Gieling (e.m.gieling@umcutrecht.nl)., van der Linden PD; Tergooi, afd. Klinische Farmacie, Hilversum., Sinha B; UMCG, afd. Medische Microbiologie & Infectiepreventie, Groningen., de Boer MGJ; LUMC, afd. Infectieziekten, Leiden. |
| Jazyk: |
Dutch; Flemish |
| Zdroj: |
Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2020 Jun 02; Vol. 164. Date of Electronic Publication: 2020 Jun 02. |
| Abstrakt: |
On 3 March 2020, the document 'Drug treatment options for patients with COVID-19 (infections with SARS-CoV-2)' was published on the website of the Dutch Working Party on Antibiotic Policy (StichtingWerkgroepAntibioticabeleid, SWAB). Based on a 7-step analysis of the literature, hydroxychloroquine (HCQ) and chloroquine (CQ) were initially included in the SWAB document as possible drug treatments for hospitalised adult COVID-19 patients. However, recent weeks have seen the publication of the results of various studies into the effectiveness of treatment with HCQ and CQ in patients with COVID-19. On the basis of these results, we conclude that there is insufficient evidence to consider HCQ and CQ as meaningful treatment options in patients with COVID-19. Clinically relevant QTc prolongation occurs in at least 1 in 10 COVID-19 patients treated with HCQ or HQ. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
